Decreasing Incidence of Chemosensory Changes by COVID‐19 Variant

Anecdotal clinical observation suggests that rates of chemosensory dysfunction associated with COVID‐19 infection may be decreasing. To investigate, the National COVID Cohort Collaborative database was queried for all patients with and without smell and taste loss within 2 weeks of COVID‐19 diagnosis. Six‐week periods of peak variant prevalence were selected by using CoVariants.org for analysis. Of 3,678,214 patients with COVID‐19 in the database, 616,318 met inclusion criteria during the time intervals of interest, with 3431 having an associated smell or taste disturbance diagnosis. With the initial/untyped variant set as the baseline, the odds ratios for alpha, delta, and omicron (December 27, 2021–February 7, 2022) were 0.50 (95% CI, 0.45‐0.55; P < .0001), 0.44 (95% CI, 0.41‐0.48; P < .0001), and 0.17 (95% CI, 0.15‐0.18; P < .0001), respectively. These data strongly support the clinical observation that patients infected with more recent variants are at a significantly lower risk of developing associated chemosensory loss.